Charles River Labs Stock - Analyst views and long-term positioning

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 13:18 UTC. Details in the imprint.

Charles River Labs (US1591881009) remains a key name in the global contract research sector. With no fresh corporate announcements on Saturday, the focus turns to how the stock is valued against analyst expectations and the company’s long-term growth drivers.

How analysts view the stock

Analyst coverage for Charles River Laboratories International remains broad, with consensus data showing a range of ratings from Buy to Hold and a spread of earnings estimates stretching into 2026.

According to one consensus overview, the company has guided full-year 2026 earnings per share to a range around the low-teens dollar level, slightly bracketing analyst estimates that cluster close to the midpoint of this corridor.

Long-term growth and business positioning

On Saturdays, investors often step back from day-to-day headlines and look at how a business is positioned structurally. For Charles River Labs, the long-term story centers on outsourced preclinical research, safety testing and biologics services for the pharmaceutical and biotech industry.

Global drug developers continue to rely on specialized contract research partners to shorten development timelines and manage fixed costs. Charles River Labs has built a broad portfolio spanning discovery research models, safety assessment and manufacturing support for complex biologic therapies.

The product behind the stock

Charles River Laboratories generates revenue primarily by providing preclinical research services, including in vivo and in vitro testing, safety assessment and biologics development support for pharmaceutical, biotechnology and academic customers worldwide. The company also supplies research models and related services used in early-stage drug discovery.

Where the stock trades today

Charles River Labs shares (US1591881009) most recently traded on the New York Stock Exchange at around $185 per share as of 06/18/2026, 15:59 Eastern Time.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.